Page 549 - Read Online

Page 6 of 7 Boortalary et al. Hepatoma Res 2020;6:48 I http://dx.doi.org/10.20517/2394-5079.2020.38

Made contributions to surgical aspects of the paper: Rosato E
Made contributions to radiological imaging: Roth C
Made contributions on providing details on HBV DNA assay: Ren XD
Made contributions to concept of OBI-HCC: Lin SY

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
Dr. Hie-Won Hann has received research grants from Gilead Sciences, Assembly Biosciences, Trio-Health
and has served on the National Advisory Board of Gilead.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and c viruses
worldwide. Int J Cancer 2018;142:2471-7.
2. Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS, et al. Update of the statements on biology and clinical impact of
occult hepatitis B virus infection. J Hepatol 2019;71:397-408.
3. Conjeevaram HS, Lok AS. Occult hepatitis B virus infection: a hidden menace? Hepatology 2001;34:204-6.
4. Kim YS, Jang JY, Eun SH, Cheon YK, Kim YS, et al. Detection of intrahepatic HBV DNA in hbsag-negative liver diseases. Korean J
Hepatol 2006;12:201-8.
5. Pollicino T, Raimondo G. Occult hepatitis B infection. J Hepatol 2014;61:688-9.
6. Wong SY, Ren XD, Hann HW. Development of hepatocellular carcinoma in patients with chronic hepatitis B long after achieving hbsag
seroconversion: a need for an improved hepatitis B virus DNA assay. Clin Microbiol 2013;2:127.
7. Loeb KR, Jerome KR, Goddard J, Huang ML, Cent A, et al. High-throughput quantitative analysis of hepatitis B virus DNA in serum
using the taqman fluorogenic detection system. Hepatology 2000;32:626-9.
8. Chen CJ, Yang HI, Su J, Jen CL, You SL, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus
DNA level. JAMA 2006;295:65-73.
9. Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine
risk for hepatocellular carcinoma. Gastroenterology 2011;141:1240-8, 1248.e1-2.
10. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma
in patients with low HBV load. Gastroenterology 2012;142:1140-9.e3; quiz e13-4.
11. Pitini V, Rizzo M, Arrigo C, Mondello P, Altavilla G. Fatal hepatocellular carcinoma in a patient with occult hepatitis B virus infection
following the administration of R-chop for diffuse large B-cell lymphoma. Case Rep Hematol 2012;2012:803298.
12. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in
lymphoproliferative diseases: Meta-analysis and examination of fda safety reports. Ann Oncol 2011;22:1170-80.
13. Wong DK, Huang FY, Lai CL, Poon RT, Seto WK, Fung J, et al. Occult hepatitis B infection and HBV replicative activity in patients with
cryptogenic cause of hepatocellular carcinoma. Hepatology 2011;54:829-36.
14. Shim CW, Park JW, Kim SH, Kim JS, Kim BH, et al. Noncirrhotic hepatocellular carcinoma: Etiology and occult hepatitis B virus
infection in a hepatitis B virus-endemic area. Therap Adv Gastroenterol 2017;10:529-36.
15. Muto J, Sugiyama M, Shirabe K, Mukaide M, Kirikae-Muto I, et al. Frequency and characteristics of occult hepatitis B infection among
hepatocellular carcinoma patients in japan. Ann Hepatol 2018;17:596-603.
16. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of
occult HBV infection. Gastroenterology 2004;126:102-10.